Neurodegenerative Diseases Drugs Market Exhibits 7.2% CAGR, Increasing Prevalence of Neurodegenerative Diseases to Foster Growth

1

• Neurodegenerative Diseases Drugs Market Exhibits
  7.2 CAGR, Increasing Prevalence of
  Neurodegenerative Diseases to Foster Growth
• The Global Neurodegenerative Diseases Drugs
  Market growth is expected to derive growth from
  the rising prevalence of neurodegenerative
  diseases especially among the aging population.
  Fortune Business Insights in a report, titled
  Neurodegenerative Diseases Drugs Global Market
  Analysis, Insights and Forecast, 2019-2026
  offers valuable insights into the trends
  prevailing in the market. In 2018, the global
  market was valued at US35,497.3 Mn and is
  projected to be worth US 62,786.2 Mn by 2026.
  At this pace, the global market is estimated to
  exhibit a healthy CAGR of 7.2 during the
  forecast duration.
• Browse Complete Report Details at
  https//www.fortunebusinessinsights.com/industry-
  reports/neurodegenerative-diseases-drugs-market-1
  00661
• Some of the major companies that are present in
  the Global Neurodegenerative Diseases Drugs
  Market are
• Biogen
• Pfizer
• Roche
• Novartis
• Sanofi
• Teva Pharmaceuticals
• Orion Pharma Ltd
• UCB S.A
• ACADIA Pharmaceuticals Inc.
• Lundbeck Pharmaceuticals Italy S.p.A.
• Mitsubishi Tanabe Pharma America
• Other players
• Neurodegenerative diseases include Alzheimers,
  multiple sclerosis, Huntington's disease,
  Parkinsons disease, multiple system atrophy,
  spinal muscular atrophy, and others. Among these,
  Alzheimers is the most prevalent diseases as
  per the Alzheimer's Association.

2

• As per a study conducted by the Parkinsons
  Association in 2018, around 1.2 million people in
  the
• U.S are estimated to be suffering from
  Parkinsons disease by 2030. With the continuous
  rise in population, this disease is projected to
  double between 2018 and 2026. Considering these
  numbers, the market is likely to grow in North
  America. This, coupled with favorable healthcare
• reimbursement policies and rising research and
  development (RD) investments is driving the
  market in this region.
• The market in Asia Pacific is anticipated to
  report a considerable CAGR primarily on account
  of rising geriatric population.
• Introduction
• Research Scope
• Market Segmentation
• Research Methodology
• Definitions and Assumptions
• Executive Summary
• Market Dynamics
• Market Drivers
• Market Restraints
• Market Opportunities
• 3.4 Market Trends
• Key Insights
• Prevalence of Neurodegenerative Diseases - For
  Key Countries, 2018
• Regulatory Scenario - For Key Countries
• Patent Snapshot

3
As per research studies, the prevalence of
neurodegenerative diseases among all genders,
races, geographical backgrounds, and genders is
likely to increase with the rising worldwide
population. Rapid lifestyle alterations such as
improper sleeping, high-stress levels, and
unhealthy eating habits are likely to result in
degenerative of nerve cells. This is further
expected to augment demand for neurodegenerative
disease treatment drugs. Medical practitioners
and physicians are becoming more aware of the
neurodegenerative disease treatment, which in
turn is enabling neurodegenerative disease drug
development. Moreover, several advancements are
expected to offer an early diagnosis of these
life-threatening diseases. A recent innovation
in neurodegenerative disease drug discovery
includes some therapies such as NDMA and
dopamine inhibitors. These innovations are
anticipated to register progressive growth in
the neurodegenerative disease drugs market. As
per disease indication, multiple sclerosis
segment is gaining traction owing to positive
governments recommendations. Further to this,
this segment covered a share of 66.1 in the
global market in 2028. In addition to this, the
high cost of drugs and new product launches are
compelling growth in this segment. For instance,
Novartis manufactured a drug called Mayzent and
this drug received FDA approval in Match 2019.
This is further expected to propel growth in
this segment in the forecast years. Biogens
Strategic Initiatives Helps the Company to Earn
More Profits In the year 2018, Biogen was
dominating the global market. Neurodegenerative
disease drug discovery and some important
strategic decisions help the company to gain more
attention. The launch of a drug called SPINRAZA
and increasing sales of another drug called
Tecfidera in 2018 helped the company to
strengthen its product portfolio. Also, the
company entered into a strategic partnership
with F. Hoffmann-La Roche Ltd. to ensure robust
distribution of drugs. This, together with the
launch of two new drugs called Madopar and
Ocrevus helped F. Hoffmann-La Roche Ltd. to gain
the second position in the market. Novartis AG
launched a new drug called Gilenya to gain a
competitive edge over others. Some of the other
leading players functioning in the global
neurodegenerative diseases drugs market are
Pfizer, Inc., H. Lundbeck A/S, Sanofi, Teva
Pharmaceutical Industries Ltd., Orion Pharma,
Merck Co., Inc., UCB S.A, Mitsubishi Tanabe
Pharma Corporation, and ACADIA Pharmaceuticals
Inc. Speak To Analyst at https//www.fortunebusine
ssinsights.com/enquiry/speak-to-
analyst/neurodegenerative-diseases-drugs-market-10
0661 About us Fortune Business Insights offers
expert corporate analysis and accurate data,
helping organizations of all sizes make timely
decisions. We tailor innovative solutions for our
clients, assisting them address challenges
distinct to their businesses. Our goal is to
empower our clients with holistic market
intelligence, giving a granular overview of the
market they are operating in.
4
Our reports contain a unique mix of tangible
insights and qualitative analysis to help
companies achieve sustainable growth. Our team
of experienced analysts and consultants use
industry- leading research tools and techniques
to compile comprehensive market studies,
interspersed with relevant data. At Fortune
Business Insights we aim at highlighting the most
lucrative growth opportunities for our clients.
We therefore offer recommendations, making it
easier for them to navigate through
technological and market-related changes. Our
consulting services are designed to help
organizations identify hidden opportunities and
understand prevailing competitive challenges.